SWM
GMAB icon

SHP Wealth Management’s Genmab GMAB Stock Holding History

SHP Wealth Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27 Sell
1
-20
-95% -$599 ﹤0.01% 1803
2025
Q4 		$647 Buy
+21
New +$655 ﹤0.01% 1327

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

SHP Wealth Management's GMAB Position: Q1 2026 in Review

SHP Wealth Management reduced its Genmab (GMAB) stake by 95% in Q1 2026, selling an estimated $599 and leaving 1 share worth $27. The position accounts for ﹤0.01% of the portfolio, ranked #1803.

SHP Wealth Management first reported a position in GMAB in Q4 2025 and has held it in 2 quarters since. The position peaked at $647 in Q4 2025. 274 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • SHP Wealth Management held 1 share of Genmab worth $27 as of Q1 2026.
  • SHP Wealth Management sold 20 Genmab shares in Q1 2026, an estimated $599.
  • Genmab made up ﹤0.01% of SHP Wealth Management's portfolio in Q1 2026, its #1803 holding.
  • SHP Wealth Management first reported a position in Genmab in Q4 2025 and has held it in 2 quarters since.
  • SHP Wealth Management's Genmab position peaked at $647 in Q4 2025.
  • 274 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.